Codexis, Inc.
CDXS
Rank in Stocks
#18829
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development,... Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Share Price
$1.11
Last synced: 2026-11-09
Market Cap
$121.55M
Change (1 day)
2.78%
Change (1 year)
-38.33%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Codexis, Inc. (CDXS)
Category
Healthcare
Operating Margin for Codexis, Inc. (CDXS)
Operating Margin as of November 2026 TTM: -31.23%
According to Codexis, Inc.'s latest financial reports, its current operating margin (TTM) is -31.23%. At the end of 2025 the company had an operating margin of -54.46%.
Operating Margin history for Codexis, Inc. from 2006 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -31.23% | -42.66% |
| 2025 | -54.46% | -44.77% |
| 2024 | -98.61% | 1.62% |
| 2023 | -97.04% | 285.54% |
| 2022 | -25.17% | 16.15% |
| 2021 | -21.67% | -37.44% |
| 2020 | -34.64% | 88.98% |
| 2019 | -18.33% | -1.66% |
| 2018 | -18.64% | -59.41% |
| 2017 | -45.92% | 161.80% |
| 2016 | -17.54% | -5.65% |
| 2015 | -18.59% | -65.66% |
| 2014 | -54.13% | -58.01% |
| 2013 | -128.90% | 272.97% |
| 2012 | -34.56% | 169.16% |
| 2011 | -12.84% | 93.08% |
| 2010 | -6.65% | -69.98% |
| 2009 | -22.15% | -74.57% |
| 2008 | -87.11% | -42.45% |
| 2007 | -151.36% | -2.45% |
| 2006 | -155.16% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -101.24% |
US
|
|
| -149.01% | -95.23% |
US
|
|
| 25.57% | -100.82% |
AU
|
|
| 31.23% | -101.00% |
BE
|
|
| 29.35% | -100.94% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Codexis, Inc.'s operating margin
What is Codexis, Inc.'s operating margin?
Codexis, Inc.'s operating margin is -31.23%, as of Nov 2026.
What was Codexis, Inc.'s operating margin in 2025?
In 2025, Codexis, Inc.'s operating margin was -54.46%, compared with -98.61% in 2024.
How has Codexis, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Codexis, Inc.'s operating margin was highest in 2021 (-21.67%) and lowest in 2024 (-98.61%).
How does Codexis, Inc.'s operating margin compare with similar companies?
Codexis, Inc.'s operating margin (-31.23%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.